Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis

Hepatology. 2022 Aug;76(2):303-316. doi: 10.1002/hep.32426. Epub 2022 Mar 15.

Abstract

Background and aims: We investigated associations between ethnicity, survival, and disease severity in a diverse Canadian cohort of patients with primary biliary cholangitis (PBC).

Approach and results: Patients with PBC were included from the Canadian Network for Autoimmune Liver Disease. Ethnicity was defined using a modified list adopted from Statistics Canada, and ethnicities with small samples were grouped. Clinical events were defined as liver decompensation, HCC, liver transplantation, or death. Clinical event-free and liver transplantation-free survival were analyzed using Cox regression. Trajectories of serum liver function tests were assessed over time using mixed-effects regression. Health-related quality of life was assessed using the Short Form 36, the PBC-40 questionnaire, and the 5-D Itch scale and analyzed using mixed-effects regression. The cohort included 1538 patients with PBC from six sites and was comprised of 82% White, 4.7% Indigenous, 5.5% East Asian, 2.6% South Asian, and 5.1% miscellaneous ethnicities. Indigenous patients were the only ethnic group with impaired liver transplant-free and event-free survival compared to White patients (HR, 3.66; 95% CI, 2.23-6.01; HR, 3.09; 95% CI, 1.94-4.92). Indigenous patients were more likely to have a clinical event before diagnosis (10%) than all other ethnic groups despite similar age at diagnosis. Indigenous patients presented with higher alkaline phosphatase, total bilirubin, and GLOBE scores than White patients; and these relative elevations persisted during follow-up.

Conclusions: Indigenous Canadians with PBC present with advanced disease and have worse long-term outcomes compared to White patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Canada / epidemiology
  • Carcinoma, Hepatocellular*
  • Cholangitis*
  • Ethnicity
  • Humans
  • Liver Cirrhosis, Biliary*
  • Liver Neoplasms*
  • Quality of Life
  • Severity of Illness Index
  • Treatment Outcome
  • Ursodeoxycholic Acid

Substances

  • Ursodeoxycholic Acid